» Articles » PMID: 21774590

High Dietary Niacin May Increase Prostaglandin Formation but Does Not Increase Tumor Formation in ApcMin/+ Mice

Overview
Journal Nutr Cancer
Publisher Routledge
Date 2011 Jul 22
PMID 21774590
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

High doses of niacin (nicotinic acid) used to treat dyslipidemias cause flushing, due to high levels of prostaglandin D(2) (PGD(2)). GPR109A, a G-protein coupled receptor, triggers the flushing in the skin. In addition to boosting PGD(2), niacin binding to GPR109A activates the entire prostanoid cascade. We found that GPR109A occurs throughout the gastrointestinal tract. Mice that alternated between a 1% niacin diet and a control diet had higher urinary prostaglandin E(2) (PGE(2)) metabolite levels when on niacin (2.8-fold increase; 95% confidence interval, 1.8-3.9). PGE(2) promotes tumors in the intestines, whereas PGD(2) may have an opposite effect, on the basis of our report showing that transgenic hematopoietic prostaglandin D synthase suppresses intestinal adenomas in Apc(Min/+) mice. To determine if either tumor growth or tumor suppression prevails, we fed Apc(Min/+) mice a 1% niacin diet and assessed tumor development. A 1% niacin diet did not affect the number of tumors scored histologically in Apc(Min/+) mice at 14 wk (33 mice on niacin, 33 controls). Although niacin stimulates production of various prostaglandins, our results support an interpretation that very high intakes of niacin are safe in relation to intestinal tumors in this model.

Citing Articles

Intestinal tumor suppression in ApcMin/+ mice by prostaglandin D2 receptor PTGDR.

Tippin B, Kwong A, Inadomi M, Lee O, Park J, Materi A Cancer Med. 2014; 3(4):1041-51.

PMID: 24729479 PMC: 4303173. DOI: 10.1002/cam4.251.

References
1.
Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen B, Ahmed K . Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010; 120(8):2910-9. PMC: 2912194. DOI: 10.1172/JCI42273. View

2.
Toth B . Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology. 1983; 40(1):72-5. DOI: 10.1159/000225695. View

3.
Cheng K, Wu T, Wu K, Sturino C, Metters K, Gottesdiener K . Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006; 103(17):6682-7. PMC: 1458941. DOI: 10.1073/pnas.0601574103. View

4.
Morrow J, Awad J, OATES J, Roberts 2nd L . Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992; 98(5):812-5. DOI: 10.1111/1523-1747.ep12499963. View

5.
STERN R, Spence J, Freeman D, Parbtani A . Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991; 50(1):66-70. DOI: 10.1038/clpt.1991.104. View